Literature DB >> 10329371

Binding of gelsolin, a secretory protein, to amyloid beta-protein.

V P Chauhan1, I Ray, A Chauhan, H M Wisniewski.   

Abstract

Soluble amyloid beta-protein (Abeta) is normally present in the cerebrospinal fluid (CSF) and plasma. However, it is fibrillized and deposited as plaques in the brains of patients with Alzheimer's disease. Cerebrospinal fluid (CSF) contains several circulating proteins (apolipoprotein E, apolipoprotein J, and transthyretin) that bind to Abeta. We report here that gelsolin, a secretory protein, also binds to Abeta in a concentration-dependent manner. Under similar conditions, other proteins such as G-actin, protein kinase C, polyglutamic acid, and gelatin did not bind to Abeta. Solid phase binding assays showed two Abeta binding sites on gelsolin that have dissociation constants (Kd) of 1.38 and 2.55 microM. Abeta was found to co-immunoprecipitate along with gelsolin from the plasma, suggesting that gelsolin-Abeta complex exists under physiological conditions. The gelsolin-Abeta complex was sodium dodecyl sulfate (SDS)stable in the absence of reducing agent, but was dissociated when the SDS stop solution contained dithiothreitol (reducing agent). This study suggests that the function of secretory gelsolin in the CSF and plasma is to bind and sequester Abeta. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329371     DOI: 10.1006/bbrc.1999.0623

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

1.  Calcium induces expression of cytoplasmic gelsolin in SH-SY5Y and HEK-293 cells.

Authors:  Lina Ji; Abha Chauhan; Ved Chauhan
Journal:  Neurochem Res       Date:  2010-03-26       Impact factor: 3.996

2.  Gelsolin levels are increased in the brain as a function of age during normal development in children that are further increased in Down syndrome.

Authors:  Lina Ji; Abha Chauhan; Balu Muthaiyah; Jerzy Wegiel; Ved Chauhan
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Oct-Dec       Impact factor: 2.703

Review 3.  Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention.

Authors:  James P Solomon; Lesley J Page; William E Balch; Jeffery W Kelly
Journal:  Crit Rev Biochem Mol Biol       Date:  2012-02-24       Impact factor: 8.250

4.  Reducing available soluble β-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice.

Authors:  Julia L Gregory; Claudia M Prada; Sara J Fine; Monica Garcia-Alloza; Rebecca A Betensky; Michal Arbel-Ornath; Steven M Greenberg; Brian J Bacskai; Matthew P Frosch
Journal:  J Neuropathol Exp Neurol       Date:  2012-11       Impact factor: 3.685

5.  Charge dependent retardation of amyloid β aggregation by hydrophilic proteins.

Authors:  Anna Assarsson; Erik Hellstrand; Celia Cabaleiro-Lago; Sara Linse
Journal:  ACS Chem Neurosci       Date:  2014-02-06       Impact factor: 4.418

6.  Gelsolin restores A beta-induced alterations in choroid plexus epithelium.

Authors:  Teo Vargas; Desiree Antequera; Cristina Ugalde; Carlos Spuch; Eva Carro
Journal:  J Biomed Biotechnol       Date:  2010-03-25

Review 7.  The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme: a biological perspective.

Authors:  Matías B de Tullio; Laura Morelli; Eduardo M Castaño
Journal:  Prion       Date:  2008-05-01       Impact factor: 3.931

Review 8.  Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease.

Authors:  Esther S Oh; Juan C Troncoso; Stina M Fangmark Tucker
Journal:  Neuromolecular Med       Date:  2008-06-10       Impact factor: 3.843

Review 9.  Cystatin C in aging and in Alzheimer's disease.

Authors:  Paul M Mathews; Efrat Levy
Journal:  Ageing Res Rev       Date:  2016-06-19       Impact factor: 10.895

10.  Proteomic analysis of Alzheimer's disease cerebrospinal fluid from neuropathologically diagnosed subjects.

Authors:  Chera L Maarouf; Tracy M Andacht; Tyler A Kokjohn; Eduardo M Castaño; Lucia I Sue; Thomas G Beach; Alex E Roher
Journal:  Curr Alzheimer Res       Date:  2009-08       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.